XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Equity Incentive Plans and ESPP (Tables)
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]  
Schedule of Stock Option Plans
A summary of the status of the Company’s option plans as of September 30, 2020 and changes during the period then ended is presented below: 
Nine months ended September 30, 2020
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year10,350,810 $20.40 
Granted861,551 70.56 
Exercised(1,260,709)14.16 
Forfeited and canceled(183,758)19.26 
Outstanding as of September 30, 20209,767,894 $25.65 
Exercisable options4,858,926 $16.84 
Schedule of RSUs and PSUs A summary of the status of the Company’s RSUs and PSUs as of September 30, 2020 and changes during the period then ended is presented below.
Nine months ended September 30, 2020
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year1,474,395 $30.26 
Granted (1)3,923,573 55.06 
Vested(906,108)21.31 
Forfeited and cancelled(24,394)48.49 
Unvested as of September 30, 20204,467,466 53.76 
(1) Includes RSUs and PSUs granted on March 3, 2020 as follows: (a) 527,041 RSUs that are expensed based on their grant date fair value of $69.37 per RSU over the service period of three years; (b) 408,539 PSUs that have a mix of service and clinical milestone vesting conditions, cliff-vest in pre-determined increments, and that have been deemed probable to vest and are therefore expensed beginning in the first quarter of 2020 based on their grant date fair value of $69.37 per PSU; (c) 108,113 PSUs that have a mix of service and clinical milestone vesting conditions, cliff-vest in pre-determined increments, and that will begin to be expensed at $69.37 per PSU when it becomes probable that the milestones will be achieved, and (d) 2,703,852 PSUs that have a mix of service, market and other milestone performance vesting conditions (including but not limited to new FDA approved indications), cliff-vest in pre-determined increments, and have a compensation cost of $48.16 per PSU that will not be recognized until the performance condition becomes probable. Also includes RSUs and PSUs granted on September 1, 2020 as follows: (a) 25,090 RSUs that are expensed based on their grant date fair value of $84.68 per RSU over the service period of three years; (b) 17,712 PSUs that have a mix of service and clinical milestone vesting conditions, cliff-vest in pre-determined increments, and that have been deemed probable to vest and are therefore expensed beginning in the third quarter of 2020 based on their grant date fair value of $84.68 per PSU; and (c) 17,712 PSUs that have a mix of service and clinical milestone vesting conditions, cliff-vest in pre-determined increments, and that will begin to be expensed at $84.68 per PSU when it becomes probable that the milestones will be achieved. The PSUs vest no earlier than three years from the date of grant and no later than six years from the date of grant. The grant date fair value of PSUs with market vesting conditions were obtained by using Monte Carlo simulations. The Company accounts for share-based compensation in accordance with ASC 718.
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: 
Nine months ended September 30,Year ended December 31,
2019
20202019
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-6.25
5.50-6.50
5.50-6.5
Expected volatility
54%-56%
55%-61%
55%-61%
Risk-free interest rate
0.30%-0.86%
1.90%-2.40%
1.73%-2.40%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
47%-66%
44%-62%
44%-62%
Risk-free interest rate
0.17%-1.57%
2.10%-2.51%
2.10%-2.51%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2020 and 2019 and the year ended December 31, 2019 was:
Three months ended September 30,Nine months ended September 30,Year ended December 31,
2019
2020201920202019
UnauditedUnauditedAudited
Cost of revenues$767 $605 $1,916 $1,626 $2,231 
Research, development and clinical trials5,101 2,202 12,275 5,203 7,570 
Sales and marketing4,677 3,368 13,061 8,585 11,897 
General and administrative9,576 8,163 28,196 22,305 30,718 
Total share-based compensation expense$20,121 $14,338 $55,448 $37,719 $52,416